CE Disclosures and Faculty Information

• TARGET AUDIENCE
  
  This activity has been designed to meet the educational needs of medical oncologists and other healthcare providers involved in the treatment of colorectal cancer (CRC).
  
  OVERVIEW OF ACTIVITY
  
  
  Cancer of the colon and rectum is the fourth most frequently diagnosed cancer and the second most common cause of death among all neoplasms in both men and women in the United States. Because of the high incidence and lethality of the disease, extensive clinical research has been undertaken in an attempt to find better treatments and possible cures. Unfortunately, in the past 5 years these efforts have yielded little in terms of new systemic therapeutic options for this disease.
   
  However, an improved understanding of the biology of these tumors and the recent publication of several pivotal data sets have dramatically increased the collective enthusiasm that one day soon a number of new and effective therapies may be available to patients. To shed light on where we are and where we are headed with regard to the treatment of metastatic CRC (mCRC), these proceedings from a CME symposium at the 2012 ASCO Annual Meetings use the perspectives of clinical investigators to prepare clinicians for the impending introduction of potentially beneficial and exciting new strategies. By providing access to the latest research developments and expert opinions on this disease, this activity will assist medical oncologists and other healthcare providers in the formulation of up-to-date clinical management strategies for mCRC.
  
  LEARNING OBJECTIVES
  • Identify patient and tumor characteristics that enable the safe and efficacious use of combination chemobiologic regimens for advanced CRC.
  • Effectively apply the results of practice-changing clinical research in the selection and sequencing of chemobiologic regimens for patients with mCRC.
  • Individualize local and systemic treatment for patients with mCRC that is isolated to the liver.
  • Recall new data with investigational agents demonstrating promising activity in CRC.
  • Employ case-based learning to refine or validate your existing CRC-specific treatment algorithms.

  ACCREDITATION STATEMENT
  
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  
  This CME activity consists of a video component. To receive credit, the participant should watch the video.
  
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Dirk Arnold, MD
  Director, Hubertus Wald Tumor Center
  University Cancer Center Hamburg
  University Hospital Eppendorf
  Hamburg, Germany
  
  Advisory Committee and Speakers Bureau: Amgen Inc, Merck Serono, Roche Laboratories Inc, Sanofi; Consulting Agreement: Bayer HealthCare Pharmaceuticals; Paid Research: Roche Laboratories Inc.
  
  Howard S Hochster, MD
  Associate Director (Clinical Research)
  Yale Cancer Center
  Professor of Medicine
  Yale School of Medicine
  New Haven, Connecticut
  
  Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Myriad Genetics Inc, Sanofi; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Genomic Health Inc, Sanofi; Speakers Bureau: Genomic Health Inc.
  
  Eric Van Cutsem, MD, PhD
  Professor of Medicine
  Digestive Oncology
  University Hospital Gasthuisberg/Leuven
  Leuven, Belgium
  
  Research Grants: Amgen Inc, Merck Serono, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc.
  
  Alan P Venook, MD
  Professor of Clinical Medicine
  University of California, San Francisco
  San Francisco, California
  
  Advisory Committee: Myriad Genetics Inc; Paid Research: Bayer HealthCare Pharmaceuticals, Genentech BioOncology, GlaxoSmithKline.
  
  John R Zalcberg, MBBS, PhD
  Chief Medical Officer and Executive Director
  Cancer Medicine
  Peter MacCallum Cancer Centre
  Melbourne, Australia
  
  Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Merck Serono, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi; Research Support: Abbott Laboratories, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genzyme Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Merck Serono, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi; Speakers Bureau: Merck Serono, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Pharmaceuticals.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by an educational grant from Regeneron Pharmaceuticals and Sanofi.
  
  Hardware/Software Requirements:
  A high-speed Internet connection 
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
  Adobe Flash Player 10.2 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: September 2012
  Expiration date: September 2013